Medlab Clinical Ltd

ASX:MDC ISIN:AU000000MDC8

Medlab LtdMedlab Clinical Limited (ASX:MDC) is pioneering the development and Commercialisation of a delivery platform, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab's pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. Patented lead drug candidate NanaBis(TM) has been developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis(TM) may be equally effective in non-cancer neuropathic pain. NanoCelle(R), the patented delivery platform is wholly owned by Medlab and developed in Medlab's owned OGTR Registered Laboratory. NanoCelle(R) is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia (Head Office), USA, and the UK.

  

News

Medlab Clinical Ltd (ASX:MDC) Executes Master Services Agreement with WEP Clinical Ltd

🕔7/23/2021 3:05:35 PM 9597

Medlab Clinical Ltd (ASX:MDC), an Australian biotech using delivery platforms to enhance medicines is pleased to announce the execution of a Master Services Agreement with WEP Clinical Ltd for the exclusive development and delivery of Named Patient Programmes

Read Full Article
###

699 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 25) (Last 30 Days: 130) (Since Published: 699) 

Company Data

    Headquarters
  • 66 McCauley Street
    Alexandria, NSW 2015
    Australia
  • Telephone
  • 02 8188 0311  
  • Fax
  • 02 9699 3347 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Healthcare 
  • Homepage
  • www.medlab.co
  • E:
  • hello@medlab.co

Social Media